Lamivudine

Chronic Hepatitis B Infection, HIV
Treatment
3 FDA approvals
20 Active Studies for Lamivudine

What is Lamivudine

LamivudineThe Generic name of this drug
Treatment SummaryDideoxycytidine (ddC) is a medication used to treat HIV-1 and hepatitis B. It is a type of reverse transcriptase inhibitor, which means it stops the virus from replicating. It is a type of zalcitabine analog, which means it contains a sulfur atom instead of a carbon atom in the pentose ring.
Epiviris the brand name
Lamivudine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Epivir
Lamivudine
1995
178

Approved as Treatment by the FDA

Lamivudine, otherwise known as Epivir, is approved by the FDA for 3 uses like HIV and Chronic Hepatitis B Infection .
HIV
Used to treat Human Immunodeficiency Virus Type 1 (HIV-1) Infection in combination with Abacavir
Chronic Hepatitis B Infection
HIV

Effectiveness

How Lamivudine Affects PatientsLamivudine is a drug that helps fight HIV-1 and hepatitis B. It works by preventing the virus from making more copies of its DNA. When Lamivudine is converted into its active form, it targets the virus’s reverse transcriptase enzyme, which is responsible for making DNA copies. Lamivudine interrupts the process of DNA copying, which keeps the virus from multiplying.
How Lamivudine works in the bodyLamivudine is a drug that stops the spread of HIV and hepatitis B by interrupting the replication process of the virus. It works by being converted into an active form inside the cells and then inserted into the virus' DNA, causing it to stop replicating.

When to interrupt dosage

The proposed dosage of Lamivudine is contingent upon the diagnosed state. The quantity of dosage fluctuates as per the delivery procedure outlined in the table below.
Condition
Dosage
Administration
HIV
30.0 mg, , 300.0 mg, 100.0 mg, 5.0 mg/mL, 150.0 mg, 10.0 mg/mL
, Solution - Oral, Tablet, Tablet - Oral, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Kit; Tablet, film coated - Oral, Solution, Tablet, coated - Oral, Kit; Tablet, film coated
Chronic Hepatitis B Infection
30.0 mg, , 300.0 mg, 100.0 mg, 5.0 mg/mL, 150.0 mg, 10.0 mg/mL
, Solution - Oral, Tablet, Tablet - Oral, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Kit; Tablet, film coated - Oral, Solution, Tablet, coated - Oral, Kit; Tablet, film coated

Warnings

There are 20 known major drug interactions with Lamivudine.
Common Lamivudine Drug Interactions
Drug Name
Risk Level
Description
Aclidinium
Minor
Lamivudine may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Lamivudine may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Lamivudine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Allylestrenol
Minor
Lamivudine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
Almasilate
Minor
Lamivudine may decrease the excretion rate of Almasilate which could result in a higher serum level.
Lamivudine Toxicity & Overdose RiskCommon side effects of taking this drug are headache, feeling sick, tiredness, blocked or runny nose, diarrhea, and coughing.

Lamivudine Novel Uses: Which Conditions Have a Clinical Trial Featuring Lamivudine?

At present, 125 active clinical trials are examining the effectiveness of Lamivudine in combating Chronic Hepatitis B.
Condition
Clinical Trials
Trial Phases
HIV
118 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4
Chronic Hepatitis B Infection
5 Actively Recruiting
Phase 3, Phase 2

Lamivudine Reviews: What are patients saying about Lamivudine?

5Patient Review
1/28/2008
Lamivudine for HIV
This treatment is effective with few side effects.

Patient Q&A Section about lamivudine

What are side effects of lamivudine?

"The following are symptoms of the flu: coughing, diarrhea, fatigue, headache, malaise, nasal symptoms, such as a runny nose, and nausea." - Anonymous Online Contributor

Unverified Answer

What is lamivudine 100mg used for?

"This medication is meant to treat adults with chronic hepatitis B who also have liver disease that is still active, as shown by high ALT levels and/or evidence of liver inflammation and/or fibrosis." - Anonymous Online Contributor

Unverified Answer

Is lamivudine an antibiotic?

"Lamivudine is an antiretroviral medication that reduces the amount of HIV in the body, slowing down or preventing damage to the immune system and reducing the risk of developing AIDS-related illnesses. It is also active against hepatitis B virus (HBV)." - Anonymous Online Contributor

Unverified Answer

Can lamivudine cure hepatitis B?

"This medication is used to treat hepatitis B infection. It is a nucleoside reverse transcriptase inhibitor (NRTI) that works by slowing the growth of the virus, thereby decreasing liver damage caused by the virus. This medication is not a cure for hepatitis B and does not prevent the passing of hepatitis B to others." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Lamivudine

Image of Friends Research Institute, Inc. Office Building in Cerritos, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

ESS-HSUfor HIV/AIDS

Cerritos, CA
18+
All Sexes
The goal of this clinical trial is to test an intervention to reduce stigma among people living with HIV who use opioids and cocaine. The main question it aims to answer is: - Does reducing internalized stigma about HIV and/or drug use lead to improved HIV care outcomes? After a year spent adapting an existing intervention to be applied specifically among people living with HIV who use substances, 70 participants will be randomized to receive either treatment-as-usual or the newly adapted intervention. The intervention itself will consist of less than ten group-based meetings to discuss and work through the stigmas people commonly associate with HIV and/or drug use.
Waitlist Available
Has No Placebo
Friends Research Institute, Inc. Office Building (+1 Sites)Jesse B Fletcher, Ph.D.
Image of National Institutes of Health Clinical Center in Bethesda, United States.
Phase-Based Progress Estimates
1
Effectiveness
2
Safety

Dolutegravirfor HIV/AIDS

Bethesda, MD
18 - 55
All Sexes
Background: People with HIV take drugs to keep the amount of virus in their body low. One type of these drugs, called integrase strand transfer inhibitors (INSTIs), can cause weight gain over time. Weight gain can cause diabetes, heart disease, and other serious issues. Researchers want to understand how INSTIs cause weight changes. Objective: To see how a common INSTI, dolutegravir (DTG), affects how the body uses energy. DTG will be compared with a non-INSTI drug, tenofovir alafenamide (TAF). Eligibility: Healthy people aged 18 to 55. Design: Participants will be screened. They will have a physical exam and blood tests. They will have a nutritional assessment and tests of their heart function. Participants will have 2 inpatient stays at the clinic. Each stay will be for 11 nights, with a 3-week break between. Both DTG and TAF are gel caps swallowed once per day by mouth. Participants will take 1 drug for 8 days during each stay. Participants will have tests to see how their body uses energy: They will spend 23 continuous hours in a special room that measures how much oxygen they breathe in and how much carbon dioxide they breathe out. They will do this a total of 6 times. They will have a DEXA (dual-energy X-ray absorptiometry). DEXA is a kind of X-ray that measures body fat and bone density. They will lie on a table. Electrodes will be placed on their hands and feet to measure body fat and lean body mass. They will stand still on a platform for about 30 seconds. High-resolution laser cameras will scan their bodies.
Phase 2
Waitlist Available
National Institutes of Health Clinical CenterJanaki C Kuruppu, M.D.
Have you considered Lamivudine clinical trials? We made a collection of clinical trials featuring Lamivudine, we think they might fit your search criteria.
Image of GSK Investigational Site in Montreal, Canada.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety

Bepirovirsenfor Chronic Hepatitis B

Montreal, Canada
18+
All Sexes
This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as compared to the placebo arm. This study will have 4 stages: Double-blind treatment (bepirovirsen or placebo) for 24 weeks; Nucleos(t)ide analogue (NA) treatment for 24 weeks; NA cessation with 24 week follow up OR Continue NA for 24 weeks, follow up for further 24 weeks for participants who stopped NA treatment at Week 48. The arms will be stratified based on HBsAg level (HBsAg greater than or equal to [≥]100 international units per milliliter [IU/mL] to ≤1000 IU/mL or >1000 IU/mL to less than or equal to [≤] 3000 IU/mL) at screening. The total duration of the study, including screening (up to 45 days), the double-blind treatment stage (24 weeks), the On NA only stage (24 weeks), and the NA cessation and durability stages (48 weeks) is up to approximately 102 weeks for each participant.
Phase 3
Recruiting
GSK Investigational SiteGSK Clinical TrialsGlaxoSmithKline
Image of GSK Investigational Site in Victoria, Canada.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety

Bepirovirsenfor Chronic Hepatitis B

Victoria, Canada
18+
All Sexes
This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as compared to the placebo arm. This study will have 4 stages: Double-blind treatment (bepirovirsen or placebo) for 24 weeks; Nucleos(t)ide analogue (NA) treatment for 24 weeks; NA cessation with 24 week follow up OR Continue NA for 24 weeks, follow up for further 24 weeks for participants who stopped NA treatment at Week 48. The arms will be stratified based on HBsAg level (HBsAg greater than or equal to [≥] 100 international unit per milliliter [IU/mL] to less than or equal [≤]1000 IU/mL or greater than [>] 1000 IU/mL to ≤3000 IU/mL) at screening. The total duration of the study, including screening (up to 45 days), the double-blind treatment stage (24 weeks), the On NA only stage (24 weeks), and the NA cessation and durability stages (48 weeks) is up to approximately 102 weeks at maximum for each participant.
Phase 3
Recruiting
GSK Investigational SiteGSK Clinical TrialsGlaxoSmithKline
Image of National Institutes of Health Clinical Center in Bethesda, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Group 5for HIV/AIDS

Bethesda, MD
18 - 60
All Sexes
Background: HIV causes AIDS, a serious disease that can lead to fatal infections. HIV infection can be controlled but not cured, nor is there a vaccine to prevent it. Antibodies may offer a promising new way to prevent HIV infection. Antibodies are proteins that are naturally made by the body to fight germs. One antibody (VRC01.23LS) has been tested in the lab and was found to block HIV-like viruses. Researchers want to find out if it is safe to inject VRC01.23LS into people. Objective: To test the safety of VRC01.23LS in healthy adults. Eligibility: Healthy people aged 18 to 60 years. Design: Participants will be divided into 6 groups: Some will get 1 dose of VRC01.23LS. They will visit the clinic up to 14 times in 24 weeks. Some will get 3 doses, each 12 weeks apart. They will have 25 clinic visits over 48 weeks. For some participants, the drug will be given through a tube attached to a needle inserted into a vein in the arm. This will take about 30 minutes. Others will receive the drug as an injection under the skin in a fatty area of the belly, arm, or thigh; each dose may need up to 3 individual injections. Participants will stay in the clinic up to 8 hours on the days they receive VRC01.23LS. Participants will receive a thermometer and measuring tool. They will check their temperature daily for 7 days after they receive the study drug. They will measure any redness, swelling, or bruising at the injection site.
Phase 1
Recruiting
National Institutes of Health Clinical CenterLesia K Dropulic, M.D.
Image of Florida Department of Health, Duval County in Jacksonville, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Care Post Clinic-Wide Training And HIV Prevention Decision Support Tool (DST)for HIV/AIDS

Jacksonville, FL
18 - 45
All Sexes
To address the significant barriers to pre-exposure prophylaxis (PrEP) implementation for cisgender women and address racial inequities in HIV prevention in the United States (US), a novel approach that accounts for multilevel influences is necessary. This study is the second part (Aim 2) of a multi-component project and involves a patient- and clinic-level intervention in a public health family planning clinic in Duval County Florida, where most patients are women of color. The area has one of the highest HIV incidence rates among women in the US. The investigators developed 1) a tablet-based decision support tool (DST) that helps users learn about HIV vulnerabilities and HIV prevention strategies to inform how they consider options for reducing their likelihood of acquiring HIV, and 2) clinic-wide trainings regarding shared decision making and trauma informed care. In Aim 1 (previously completed), participants were randomized to viewing an HIV prevention DST in a clinic that had not received clinic-wide trainings. In Aim 2 (the present study), there will be two phases. In the first phase, participants will receive care at the clinic following training; the DST will not be used. In the second phase, in addition to being seen at a clinic-site that has experienced the training, participants will use the DST before their visit. Participants will be surveyed about experiences with HIV prevention counseling, intentions about using HIV prevention, and DST use (among those in the active arm in the second phase). A subset of participants, individuals who self-identify as Black or Latinx, will also complete a post-clinic visit interview. The investigators will assess whether participants initiated an HIV prevention method three months following their initial visit. The main outcomes will include a quantitative and qualitative assessment of PrEP or other HIV prevention use, decisional certainty, and satisfaction with information about HIV prevention options.
Recruiting
Has No Placebo
Florida Department of Health, Duval CountyAkilah Pope, MD
Have you considered Lamivudine clinical trials? We made a collection of clinical trials featuring Lamivudine, we think they might fit your search criteria.
Have you considered Lamivudine clinical trials? We made a collection of clinical trials featuring Lamivudine, we think they might fit your search criteria.